Cargando…

Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials

The role of a combination of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy for non-small-cell lung cancer (NSCLC) has not been well established. To clarify this problem, we performed a meta-analysis with 15 studies identified from PubMed, EMBASE and the Coc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Minghui, Guo, Hongsheng, Zhao, Shu, Wang, Yan, Yang, Maopeng, Yu, Jiawei, Yan, Yubo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129973/ https://www.ncbi.nlm.nih.gov/pubmed/27223081 http://dx.doi.org/10.18632/oncotarget.9503

Ejemplares similares

Association of Polymorphisms in Inflammation Genes With the Prognosis of Advanced Non-Small Cell Lung Cancer Patients Receiving Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Zhang, Xuelin, et al.
Publicado: (2022)

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation
por: Shang, Kai, et al.
Publicado: (2022)

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epidermal Growth Factor Receptor Mutations
por: Feng, Yongdong, et al.
Publicado: (2021)

Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
por: Wang, Yue, et al.
Publicado: (2020)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
por: Huang, Aimi, et al.
Publicado: (2016)

An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report
por: Zhou, Juan, et al.
Publicado: (2020)

Sequential chemotherapy and icotinib as first-line treatment for advanced epidermal growth factor receptor-mutated non-small cell lung cancer
por: Sun, Sheng-Jie, et al.
Publicado: (2022)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
por: Qin, Haifeng, et al.
Publicado: (2021)

Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo
por: Li, Tao, et al.
Publicado: (2021)

The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study
por: Zhang, Shuyang, et al.
Publicado: (2023)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Anti‐epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
por: Peng, Hao, et al.
Publicado: (2018)

Pooled analysis of the clinical benefit of cyclooxygenase-2 inhibitors combined with chemotherapy in advanced non-small cell lung cancer
por: Zheng, Wei, et al.
Publicado: (2019)

Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
por: Zhang, Yan, et al.
Publicado: (2017)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
por: Liang, Hongge, et al.
Publicado: (2018)

Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
por: Gao, Yuan, et al.
Publicado: (2015)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in advanced hepatocellular carcinoma: A systematic review and meta‑analysis
por: Li, Zixiong, et al.
Publicado: (2023)

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis
por: Alanazi, Abdullah, et al.
Publicado: (2020)

Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma
por: Chen, Ying-Yi, et al.
Publicado: (2023)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
por: Wang, Hai-ying, et al.
Publicado: (2020)

Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma
por: Amirabadi, Amir, et al.
Publicado: (2021)

Efficacy and safety of elemene combined with chemotherapy in advanced gastric cancer: A Meta-analysis
por: Liu, Ying, et al.
Publicado: (2020)

Efficacy and Safety of Xiao Ai Ping Injection Combined with Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kerui, et al.
Publicado: (2019)

The Efficacy of Combining Antiangiogenic Agents with Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer Who Failed First-Line Chemotherapy: A Systematic Review and Meta-Analysis
por: Sheng, Jin, et al.
Publicado: (2015)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer
por: Hu, Na, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer
por: Meriggi, F., et al.
Publicado: (2010)

Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a Bayesian network meta-analysis
por: Liu, Shu, et al.
Publicado: (2022)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Correlation between expression of epidermal growth factor receptor and adverse reactions after chemotherapy of advanced non-small-cell lung cancer
por: Hao, Zerui, et al.
Publicado: (2015)

Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer
por: Gao, Shu-Quan, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study
por: Ye, Xuanting, et al.
Publicado: (2023)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Efficacy and optimal combination timing of chemotherapy combined with PD-1 inhibitor in advanced cervical cancer: a multicenter retrospective cohort study
por: Ma, Yi-Ming, et al.
Publicado: (2022)

Molecular Dynamics Analysis of Binding Sites of Epidermal Growth Factor Receptor Kinase Inhibitors
por: Li, Dong-Dong, et al.
Publicado: (2020)

Efficacy and safety of COX-2 inhibitors for advanced non-small-cell lung cancer with chemotherapy: a meta-analysis
por: Dai, Ping, et al.
Publicado: (2018)

An exploration of LAF‐bTMB as a predictor for the efficacy of immunotherapy combined with chemotherapy in non—small cell lung cancer
por: Zhang, Shuyang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_79v6oo3eks0dhtqhuq8k99n8aq